Nothing seems to bother NYSE:PHR, NASDAQ:QLGN, NASDAQ:ATOS, NASDAQ:OPHC

Phreesia Stock Forecast, Price & News (NYSE:PHR)

Phreesia last announced its earnings results on March 31st, 2021. The reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.05. Phreesia has generated ($4.50) earnings per share over the last year. Phreesia has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, June 14th, 2021 based off prior year’s report dates.

IS PHREESIA A BUY RIGHT NOW? (NYSE:PHR)

12 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Phreesia in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Phreesia stock.
Phreesia

QUALIGEN THERAPEUTICS EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:QLGN)

IS QUALIGEN THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:QLGN)

1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Qualigen Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should “buy” Qualigen Therapeutics stock.
Qualigen Therapeutics

ATOSSA THERAPEUTICS (NASDAQ:ATOS) EARNINGS INFORMATION (NASDAQ:ATOS)

Atossa Therapeutics last announced its quarterly earnings results on March 30th, 2021. The reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by $0.61. Atossa Therapeutics has generated $0.00 earnings per share over the last year. Atossa Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, May 12th, 2021 based off prior year’s report dates.

IS ATOSSA THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:ATOS)

2 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Atossa Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Atossa Therapeutics stock.
Atossa Therapeutics

OPTIMUMBANK EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:OPHC)

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN OPTIMUMBANK? (NASDAQ:OPHC)

Wall Street analysts have given OptimumBank a “N/A” rating, but there may be better short-term opportunities in the market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OptimumBank wasn’t one of them. MarketBeat thinks these five stocks may be even better buys.